Hepatic Artery Infusion Pumps: A Surgical Toolkit for Intraoperative Decision-Making and Management of Hepatic Artery Infusion-Specific Complications.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
entrez:
8
11
2022
pubmed:
9
11
2022
medline:
11
11
2022
Statut:
ppublish
Résumé
Hepatic artery infusion (HAI) is a liver-directed therapy that delivers high-dose chemotherapy to the liver through the hepatic arterial system for colorectal liver metastases and intrahepatic cholangiocarcinoma. Utilization of HAI is rapidly expanding worldwide. This review describes the conduct of HAI pump implantation, with focus on common technical pitfalls and their associated solutions. Perioperative identification and management of common postoperative complications is also described. HAI therapy is most commonly performed with the surgical implantation of a subcutaneous pump, and placement of its catheter into the hepatic arterial system for inline flow of pump chemotherapy directly to the liver. Intraoperative challenges and abnormal hepatic perfusion can arise due to aberrant anatomy, vascular disease, technical or patient factors. However, solutions to prevent or overcome technical pitfalls are present for the majority of cases. Postoperative HAI-specific complications arise in 22% to 28% of patients in the form of pump pocket (8%-18%), catheter (10%-26%), vascular (5%-10%), or biliary (2%-8%) complications. The majority of patients can be rescued from these complications with early identification and aggressive intervention to continue to deliver safe and effective HAI therapy. This HAI toolkit provides the HAI team a reference to manage commonly encountered HAI-specific perioperative obstacles and complications. Overcoming these challenges is critical to ensure safe and effective pump implantation and delivery of HAI therapy, and key to successful implementation of new programs and expansion of HAI to patients who may benefit from such a highly specialized treatment strategy.
Sections du résumé
BACKGROUND
Hepatic artery infusion (HAI) is a liver-directed therapy that delivers high-dose chemotherapy to the liver through the hepatic arterial system for colorectal liver metastases and intrahepatic cholangiocarcinoma. Utilization of HAI is rapidly expanding worldwide.
OBJECTIVE AND METHODS
This review describes the conduct of HAI pump implantation, with focus on common technical pitfalls and their associated solutions. Perioperative identification and management of common postoperative complications is also described.
RESULTS
HAI therapy is most commonly performed with the surgical implantation of a subcutaneous pump, and placement of its catheter into the hepatic arterial system for inline flow of pump chemotherapy directly to the liver. Intraoperative challenges and abnormal hepatic perfusion can arise due to aberrant anatomy, vascular disease, technical or patient factors. However, solutions to prevent or overcome technical pitfalls are present for the majority of cases. Postoperative HAI-specific complications arise in 22% to 28% of patients in the form of pump pocket (8%-18%), catheter (10%-26%), vascular (5%-10%), or biliary (2%-8%) complications. The majority of patients can be rescued from these complications with early identification and aggressive intervention to continue to deliver safe and effective HAI therapy.
CONCLUSIONS
This HAI toolkit provides the HAI team a reference to manage commonly encountered HAI-specific perioperative obstacles and complications. Overcoming these challenges is critical to ensure safe and effective pump implantation and delivery of HAI therapy, and key to successful implementation of new programs and expansion of HAI to patients who may benefit from such a highly specialized treatment strategy.
Identifiants
pubmed: 36346892
doi: 10.1097/SLA.0000000000005434
pii: 00000658-202212000-00001
pmc: PMC9700364
mid: NIHMS1848974
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
943-956Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflict of interests.
Références
KemenyNENiedzwieckiDHollisDR Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24:1395–1403.
D’AngelicaMICorrea-GallegoCPatyPB Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and longterm outcomes. Ann Surg. 2015;261:353–360.
PakLMKemenyNECapanuM Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: long term results and curative potential. J Surg Oncol. 2018;117:634–643.
DhirMJonesHLShuaiY Hepatic arterial infusion in combination with modern systemic chemotherapy is associated with improved survival compared with modern systemic chemotherapy alone in patients with isolated unresectable colorectal liver metastases: a case-control study. Ann Surg Oncol. 2017;24:150–158.
JarnaginWRSchwartzLHGultekinDH Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol. 2009;20:1589–1595.
AntebyRKemenyNEKinghamTP Getting chemotherapy directly to the liver: the historical evolution of hepatic artery chemotherapy. J Am Coll Surg. 2021;232:332–338.
KemenyNCohenABertinoJR Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma. Cancer. 1990;65:2446–2450.
KemenyNCohenASeiterK Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol. 1993;11:330–335.
KemenyNContiJACohenA Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 1994;12:2288–2295.
KemenyNContiJASigurdsonE A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases. Cancer. 1993;71:1964–1971.
KemenyNHuangYCohenAM Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039–2048.
DalyJMKemenyNOdermanP Long-term hepatic arterial infusion chemotherapy. Anatomic considerations, operative technique, and treatment morbidity. Arch Surg. 1984;119:936–941.
AckermanNB The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery. 1974;75:589–596.
BreedisCYoungG . The blood supply of neoplasms in the liver. Am J Pathol. 1954;30:969–977.
DizonDSSchwartzJKemenyN . Regional chemotherapy: a focus on hepatic artery infusion for colorectal cancer liver metastases. Surg Oncol Clin N Am. 2008;17:759–771. viii.
PowerDGKemenyNE The role of floxuridine in metastatic liver disease. Mol Cancer Ther. 2009;8:1015–1025.
SigurdsonERRidgeJAKemenyN Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol. 1987;5:1836–1840.
BuismanFEGrunhagenDJHomsMYV Adjuvant hepatic arterial infusion pump chemotherapy after resection of colorectal liver metastases: results of a safety and feasibility study in The Netherlands. Ann Surg Oncol. 2019;26:4599–4607.
ChakedisJBealEWSunS Implementation and early outcomes for a surgeon-directed hepatic arterial infusion pump program for colorectal liver metastases. J Surg Oncol. 2018;118:1065–1073.
CreasyJMNapierKJReedSA Implementation of a hepatic artery infusion program: initial patient selection and perioperative outcomes of concurrent hepatic artery infusion and systemic chemotherapy for colorectal liver metastases. Ann Surg Oncol. 2020;27:5086–5095.
MuaddiHD’AngelicaMWisemanJT Safety and feasibility of initiating a hepatic artery infusion pump chemotherapy program for unresectable colorectal liver metastases: amulticenter, retrospective cohort study. J Surg Oncol. 2021;123:252–260.
BrajcichBCBentremDJYangAD Short-term risk of performing concurrent procedures with hepatic artery infusion pump placement. Ann Surg Oncol. 2020;27:5098–5106.
CercekABoernerTTanBR Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6:60–67.
DattaJNarayanRRKemenyNE Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases: a review. JAMA Surg. 2019;154:768–776.
DhirMMaggeDNovakS Robotic-assisted placement of an hepatic artery infusion pump and catheter for regional chemotherapy of the liver. Ann Surg Oncol. 2016;23(suppl 5):755–756.
DhirMZenatiMSPadussisJC Robotic assisted placement of hepatic artery infusion pump is a safe and feasible approach. J Surg Oncol. 2016;114:342–347.
QadanMD’AngelicaMIKemenyNE Robotic hepatic arterial infusion pump placement. HPB (Oxford). 2017;19:429–435.
UrbachDRHansenPD Laparoscopic placement of a continuous hepatic artery infusion pump. Semin Laparosc Surg. 2000;7:140–147.
PerezDRKemenyNEBrownKT Angiographic identification of extrahepatic perfusion after hepatic arterial pump placement: implications for surgical prevention. HPB (Oxford). 2014;16:744–748.
CatalanoOASinghAHUppotRN Vascular and biliary variants in the liver: implications for liver surgery. Radiographics. 2008;28:359–378.
HiattJRGabbayJBusuttilRW Surgical anatomy of the hepatic arteries in 1000 cases. Ann Surg. 1994;220:50–52.
SongSYChungJWYinYH Celiac axis and common hepatic artery variations in 5002 patients: systematic analysis with spiral CT and DSA. Radiology. 2010;255:278–288.
AllenPJNissanAPiconAI Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. JAm Coll Surg. 2005;201:57–65.
YezhelyevMOsgoodMEgnatashviliV Saphenous vein graft conduits for insertion of hepatic arterial infusion pumps in patients with abnormal hepatic arterial anatomy. J Surg Oncol. 2008;97:85–89.
AustJ . Saphenous vein graft as a conduit for hepatic artery catheters in anomalies of the hepatic arterial system. Surgery. 1986;100:581–583.
CallahanMKKemenyNE Implanted hepatic arterial infusion pumps. Cancer J. 2010;16:142–149.
SofocleousCTSchubertJKemenyN Arterial embolization for salvage of hepatic artery infusion pumps. J Vasc Interv Radiol. 2006;17:801–806.
NapierKJLidskyMEJamesOG Hepatic arterial infusion pumps: what the radiologist needs to know. Radiographics. 2021;41:895–908.
UlielLRoyalHDDarcyMD From the angio suite to the gammacamera: vascular mapping and 99mTc-MAA hepatic perfusion imaging before liver radioembolization—a comprehensive pictorial review. J Nucl Med. 2012;53:1736–1747.
OberfieldRAMcCaffreyJAPolioJ Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary. Cancer. 1979;44:414–423.
ReedMLVaitkeviciusVKAl-SarrafM The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol. Cancer. 1981;47:402–409.
TurleyMMooreCCreasyJM Resection of the primary tumor combined with hepatic artery infusion pump placement is a safe approach for unresectable colorectal liver metastases. J Gastrointest Surg. 2021. In Press.
CurleySAChaseJLRohMS Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery. 1993;114:928–935.
ItoKItoHKemenyNE Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol. 2012;19:1609–1617.
KemenyNCapanuMD’AngelicaM Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009;20:1236–1241.